Literature DB >> 27083312

Serum apelin and ADMA levels in type 2 diabetics with and without vascular complications.

Akar Karakoç1, Arzu Sahin2, Elif Simsek Polat1, Elvin Aliyev1, Abdulkadir Yildirim1, Nuri Bakan1, Eda Dokumacioglu3.   

Abstract

AIMS: Type 2 diabetes mellitus (T2DM) is a metabolic and chronic disease which is characterized by hyperglycemia, and that is the major causes of various micro and macrovascular complications. Asymmetrical dimethylarginine (ADMA), formed by the hydrolysis of proteins containing methylated arginine residues, is an endogenous inhibitor of nitric oxide synthase (NOS), which oxidize l-arginine to citruline and nitric oxide (NO), related to hyperinsulinaemia and hyperlipidaemia. Apelin is a recently discovered peptide, present in a number of tissues and play role in insulin sensitivity improvement. In this study, our aim was to determine the levels of apelin and ADMA with glycated haemoglobin (HbA1c) in type 2 diabetic patients with or without vascular complications.
METHODS: This study included (a total of) 59 diabetic patients. Of the patients, 30 were diabetic with complications, and 29 without complications. In serum samples obtained from the patients, serum ADMA and apelin levels were measured with Enzyme Linked Immunosorbent Assay (ELISA) method.
RESULTS: Our study totally enrolled 59 patients in two groups. No significant differences were found in sex, age, HbA1c and glucose levels among groups. Apelin and ADMA levels of group with complications were lower than those of group without complications, but no statistically significant difference of apelin and ADMA levels (p>0.05).
CONCLUSION: The results of this study have been showed no statistically significant relationship present between ADMA-apelin levels and complications of T2DM. Further studies involving larger patients populations and healthy controls should be done to clarify the pathogenetic significance of apelin and ADMA in diabetic vascular complications.
Copyright © 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADMA; Apelin; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 27083312     DOI: 10.1016/j.dsx.2016.03.005

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  4 in total

Review 1.  The Role of Apelin-APJ System in Diabetes and Obesity.

Authors:  Cheng Li; Hongna Cheng; Binay Kumar Adhikari; Shudong Wang; Na Yang; Wenyun Liu; Jian Sun; Yonggang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

2.  Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: Concepts and clinical practice.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Huda J Waheed; Thabat J Al-Maiahy
Journal:  J Adv Pharm Technol Res       Date:  2018 Jul-Sep

3.  Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia.

Authors:  Zhi-Min Yu; Ying Zhao; Jin-Qiong Zhan; Tao Luo; Jian-Wen Xiong; Bin Yu; Bo Wei; Yuan-Jian Yang
Journal:  Front Psychiatry       Date:  2019-01-10       Impact factor: 4.157

4.  Pioglitazone protects blood vessels through inhibition of the apelin signaling pathway by promoting KLF4 expression in rat models of T2DM.

Authors:  Ying Wang; Ruonan Zhang; Hailin Shen; Jing Kong; Xinrui Lv
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.